This page shows the latest GlycoVaxyn news and features for those working in and with pharma, biotech and healthcare.
GSK has made vaccines a pillar of its strategy since taking control of Novartis’ vaccine business in 2014, which it then followed up with a $190m deal for vaccine specialist GlycoVaxyn
Acquisition will expand GSK’s early vaccines pipeline. GlaxoSmithKline (GSK) has taken control of Swiss company GlycoVaxyn in a $190m deal that bolsters its early vaccines pipeline. ... GSK already owned a stake in GlycoVaxyn and had been working with
He said: “This collaboration is a further confirmation of the position GlycoVaxyn is about to occupy in the vaccine development space. ... The whole team is dedicated to establish GlycoVaxyn's technology as a powerful platform able to generate
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
Licence. 201. GlycoVaxyn/ GSK. Conjugation platform plus early stage vaccines against bacterial infections such as pneumonia, Pseudomonas, S.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
He will join the Swiss vaccines company in June. Swiss vaccines company GlycoVaxyn has appointed Gerd Zettlmeissl as chairman of the board of directors with effect from June, when he will
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...